No registrations found.
ID
Source
Brief title
Health condition
subarachnoidal hemorrhage
treatment in intensive care
Sponsors and support
Intervention
Outcome measures
Primary outcome
1. Pharmacokinetics of nimodipine in this specific group of patients;
2. Variability of bio-availability of orally administred nimodipine.
Secondary outcome
N/A
Background summary
The pharmacokinetics of nimodipine, intravenous and orally, in patients with subarachnoidal hemorrhage admitted in the intensive care. Use of nimodipine in this specific group of patients according to our SAB protocol. Measurement of nimodipine blood levels during intravenous and orally administration.
Study objective
Describing the pharmacokinetics of nimodipine, especially the variability of bio-availability orally administred nimdipine.
Study design
N/A
Intervention
Bloodsamples according to strict time protocol during treatment.
Afdeling intensive care volwassenen
Boelelaan 1117
B.M. Kors
Amsterdam 1081 HV
The Netherlands
+ 31 20 4443900
bm.kors@vumc.nl
Afdeling intensive care volwassenen
Boelelaan 1117
B.M. Kors
Amsterdam 1081 HV
The Netherlands
+ 31 20 4443900
bm.kors@vumc.nl
Inclusion criteria
1. All patients admitted on the ICU with subarachnoidal hemorrhage (SAB), treated according to our SAB-protocol;
2. Adults aged 18 - 70 years old.
Exclusion criteria
1. Pregnancy;
2. Expected mortality < 24 hours;
3. Severe hepatic function disorders;
4. Use of medication with know interaction in relation to nimodipine.
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| NTR-new | NL861 |
| NTR-old | NTR875 |
| Other | : N/A |
| ISRCTN | ISRCTN45381163 |